Regenerative medicine

Vesigen to Present at the 2024 Cell and Gene Meeting on the Med

Retrieved on: 
Wednesday, April 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, MED, Tissue engineering, Cell, Regenerative medicine, RNA, Gene editing, Therapy

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2024 Cell and Gene Meeting on the Med on April 10th at 10:45 AM CET in Rome, Italy.

Key Points: 
  • Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2024 Cell and Gene Meeting on the Med on April 10th at 10:45 AM CET in Rome, Italy.
  • Virtual attendance is available which includes a livestream of Vesigen’s presentation and the ability to view all conference sessions on-demand.
  • Visit https://meetingonthemed.com/ for full information including registration.
  • Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Med is a three-day conference featuring more than 60 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.

Eureka Therapeutics Announces UCSF Benioff Children’s Hospitals as First California Site for ARYA-2 Clinical Trial Targeting Pediatric Liver Cancers

Retrieved on: 
Tuesday, April 2, 2024
Stem Cells, Biotechnology, Health, Pharmaceutical, Oncology, Health Technology, Medical Devices, Research, Hospitals, Science, Clinical Trials, HCC, Clinical Pediatrics, UCSF, AFP, Regenerative medicine, Patient, Hepatoblastoma, HB, CIRM, Cancer, Doctor of Philosophy, ARTEMIS, MD, Therapy, Hepatocellular carcinoma, Liver, Pharmaceutical industry

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).

Key Points: 
  • Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).
  • The ARYA-2 trial is evaluating Eureka’s investigational ARTEMIS® ET140203 T-cell therapy which targets the alpha-fetoprotein (AFP)-peptide/HLA-A2 complex.
  • This therapy is designed to treat pediatric subjects (1 to 21 years) with relapsed or refractory liver cancer, including hepatoblastoma (HB), hepatocellular neoplasm not otherwise specified (HCN-NOS), and hepatocellular carcinoma (HCC).
  • For more information on the ARYA-2 trial, Eureka’s T-cell therapy platform, and the potential of this treatment, please visit eurekaconnectme.com .

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Retrieved on: 
Monday, April 1, 2024
Health, Stem Cells, Genetics, General Health, Research, Science, Biotechnology, Stem cell, B cell, Regenerative medicine, Agriculture, Global health, Lineage, Madrona Venture Group, Duke University, Beckman Research Institute, City, Columbia University, University, NanoString Technologies, Fierce, Doctor of Philosophy, Investment, Therapy, Microbiology, Partner, Corporate development, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.
  • Most recently, Dr. Hubbert served in the leadership team at NanoString Technologies .
  • “We are excited to add such a talented executive to our management team in the newly created position of VP Corporate Development.
  • Dr. Hubbert’s decades of experience in cell therapy, strategic investment, and partnering make her a valuable and welcome addition to the Lineage team,” stated Brian M. Culley, CEO.

Global Cell Counting Market to Hit $15.72 Billion by 2029, Fueled by Advancements in Cell Biology and Therapy - ResearchAndMarkets.com

Retrieved on: 
Friday, March 29, 2024
Research, Technology, University, Genetics, Artificial Intelligence, Education, Science, Nanotechnology, Biotechnology, Stem Cells, Other Technology, Health, Other Science, Automation, Quality control, Interdisciplinarity, Acute lymphoblastic leukemia, Growth, Prevalence, Application, Novartis, Patient, Conditional sentence, Cell biology, Lung, Concha bullosa, Hospital, Artificial intelligence, National Cancer Institute, AI, Regenerative medicine, Duchenne muscular dystrophy, Therapy, DEB, Miniaturization, Sarepta Therapeutics, CGT, FDA, DMD, Tisagenlecleucel, PDUFA, Pharmaceutical industry

The global cell counting market was valued at US$9.98 billion in 2023 and is expected to reach US$15.72 billion by 2029.

Key Points: 
  • The global cell counting market was valued at US$9.98 billion in 2023 and is expected to reach US$15.72 billion by 2029.
  • Advancements in cell biology, biotechnology, and medical research are driving demand for precise cell counting, especially with the rise of personalized medicine and regenerative therapies.
  • PDUFA dates for therapies could translate into an order book boost for the cell counting players in the market, resulting in market growth.
  • The global cell counting market is consolidated, with top five players holding approximately 70% share of the market.

Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Health, Clinical Trials, Research, Conference, TSX Venture Exchange, MSCL, Regeneration, CFO, G&A, Toronto Stock Exchange, Muscular dystrophy, Doctor of Philosophy, MD, Senior, MBA, GMP, IND, Bank statement, TSX, Regenerative medicine, Duchenne muscular dystrophy, Facioscapulohumeral muscular dystrophy, Investment, Chemistry, Toxicology, Therapy, AAK1, OTCQB, FDA, GLP, Animal, DMD, FSHD, Hand, Episcopal conference, Food, CPA, Pharmaceutical industry

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ended December 31, 2023.

Key Points: 
  • Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ended December 31, 2023.
  • Subsequent to the year end, on March 4, 2024, Satellos announced positive preclinical data presented at the Muscular Dystrophy Association Clinical and Scientific Conference.
  • Satellos also announced that SAT-3247 would be nominated as its lead development candidate with SAT-3153 becoming the backup development candidate.
  • Satellos’ audited financial statements for the year ended December 31, 2023, and the related management’s discussion and analysis (MD&A) will be available on SEDAR+ at www.sedarplus.ca .

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

Retrieved on: 
Tuesday, March 26, 2024
Research, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, FRS, Gene editing, Acute liver failure, New product development, UTHR, Patient, United Therapeutics, Lung, Xenotransplantation, Manuscript, MBBS, Regenerative medicine, PBC, Clinical trial, Therapy, Heart, Creativity, Physiology, Kidney, FACS, FRCS, Liver, Physiological Reviews, Food, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.
  • Beyond xenotransplantation, United Therapeutics has six other organ manufacturing programs in the lung, kidney, and liver using three distinct platforms: regenerative medicine, bio-artificial organs, and 3-D organ printing.
  • United Therapeutics believes that this study will be the first human clinical trial of a manufactured organ.
  • At United Therapeutics, our vision and mission are one.

Creative Medical Technology Holdings Provides Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Health, FDA, General Health, Clinical Trials, Research, Science, Biotechnology, Consultant, Toxicity, Radiation, Medicine, Urology, Immunotherapy, T1D, Patient, History, IND, Regenerative medicine, Gynaecology, Investment, IP, Investigational New Drug, Clinical trial, Safety, Pain, Share repurchase, Endocrinology, Elective surgery, Food, IRB, Pharmaceutical industry

Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024.

Key Points: 
  • Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024.
  • “In the past year our achievements have been some of the most consequential in the history of Creative Medical Technology,” said Timothy Warbington, the Company’s Chief Executive Officer.
  • We believe that our cell-based therapies have the potential to address critical unmet medical needs and are poised to pursue this objective.”
    He continued, “2023 was a year of significant achievement for Creative Medical, and our progress along multiple fronts has continued into 2024.
  • In Q1 2024, the Company announced the receipt of Orphan Drug Designation from the FDA for CELZ-101, or ImmCelz™.

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Modafinil, Research, Depression, EEG, DSM-IV codes, Histamine, Brain, Regenerative medicine, CFO, NMDA, MDD, Partnership, Patient, CNS, CIAS, Neuroscience, CIRM, Anhedonia, IPO, PDE4, Overalls, IND, Biogen, Cognition, Johnson & Johnson, Central nervous system disease, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.
  • In January 2023, Alto reported positive results from a Phase 2a study in which patients with MDD and a cognitive biomarker signature were identified as more responsive to ALTO-100.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by the cognitive biomarker.
  • The increase was primarily attributable to costs associated with the Phase 2a clinical studies for ALTO-100 and ALTO-300, which were completed in 2023.

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

Retrieved on: 
Monday, March 18, 2024
Health, Stem Cells, Genetics, Research, Science, Biotechnology, Organization, Cell, Regenerative medicine, Caregiver, Paralysis, Lineage, Quality of life, Clinical trial, Therapy, Multimedia, SCI, Human, Person, Pharmaceutical industry

The 2nd SCIIS builds upon a successful inaugural event held on June 29, 2023, and will connect a diverse set of stakeholders in the field of spinal cord injury (SCI).

Key Points: 
  • The 2nd SCIIS builds upon a successful inaugural event held on June 29, 2023, and will connect a diverse set of stakeholders in the field of spinal cord injury (SCI).
  • The 2nd SCIIS will be held on June 26 and 27, 2024 at the Sanford Consortium for Regenerative Medicine in La Jolla, CA.
  • "Our aim at Lineage is to improve recovery and mobility by replacing the cells which are destroyed following a spinal cord injury.
  • This event will bring together both public and private companies developing new treatment options for people with spinal cord injury, alongside leaders in the spinal cord injury medical and advocacy communities.

Immunis Chairman Dr. Hans Keirstead to Present Abundance360 Moonshot

Retrieved on: 
Monday, March 18, 2024
Surgery, Other Health, Other Science, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Hospitals, Technology, Fitness & Nutrition, Clinical Trials, Stem Cells, Women, Science, Biotechnology, Practice Management, Seniors, Physical Therapy, Nanotechnology, Alternative Medicine, Managed Care, Medical Supplies, Men, FDA, Health, Diabetes, Consumer, Notifiable disease, Longevity, Facial muscles, Education, Patient, Ageing, Research, Sarcopenia, DSM-IV codes, Aging Cell, Quality of life, Human, Regenerative medicine, Safety, Fix, Muscle atrophy, Dietary supplement

Immunis, Inc., a private biotech company developing an innovative secretome for age-related diseases and immune dysfunction, announces that its Chairman, Dr. Hans Keirstead, will present at the annual Abundance360 in Los Angeles.

Key Points: 
  • Immunis, Inc., a private biotech company developing an innovative secretome for age-related diseases and immune dysfunction, announces that its Chairman, Dr. Hans Keirstead, will present at the annual Abundance360 in Los Angeles.
  • In fact, Abundance360 showcases “Moonshots,” or transformative ideas, from leaders who are making excellent strides to revolutionize human healthspan.
  • Dr. Keirstead’s Moonshot aims for the incredible goal of one day treating 500M individuals with Immunis’ investigational secretome (IMMUNA) to combat age-related immune dysfunction, targeting muscle atrophy and metabolic decline.
  • Dr. Keirstead’s Moonshot with IMMUNA aligns perfectly with his “Massive Transformative Purpose” to democratize regenerative medicine and enable everyone to live healthier lives.